Cognetivity Neurosciences (CSE: CGN) has entered the mainstream. The company this morning announced that it has signed a commercial agreement with Emirates Health Services, the main federal provider of public healthcare in the UAE.
Under the commercial agreement, the company will see its Integrated Cognitive Assessment tech be deployed throughout the country. The tool is utilized as a method of screening for cognitive impairment, with its implementation to be used “to enhance the timely diagnosis of mild cognitive impairment and dementia.:
The arrangement with the Health Services will see the firms tech deployed at EHS run clinics throughout the country. The agency currently operates hundreds of healthcare centers and hospitals across the UAE. The arrangement follows the recent registration of the tech with the Ministry of Health, for which it has been cleared for medical use across the country.
Sponsored · Cambria Gold Mines
“We’re hugely excited about this latest deployment of the ICA and thrilled to confirm another major deal in the Middle East. To tackle the massive global problem of dementia, we have to begin cognitive testing on a larger scale than ever before. The ICA is the perfect tool in every way for this job and this latest implementation paves the way for further large-scale deployments in the future, which is immensely exciting,” commented CEO Dr Sina Habibi on the achievement.
Rollout of the dementia-testing tech is expected to be rapid, due to the ability of the ICA to be utilized by patients without supervision. The tech utilizes a short, simple test on a tablet that can be conducted remotely by patients, while providing an “end-to-end cognitive testing solution.”
Financial details of the arrangement were not disclosed.
Cognetivity Neurosciences last traded at $0.53 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
